Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies.
Journal
Translational research : the journal of laboratory and clinical medicine
ISSN: 1878-1810
Titre abrégé: Transl Res
Pays: United States
ID NLM: 101280339
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
22
12
2020
revised:
07
02
2021
accepted:
09
02
2021
pubmed:
15
2
2021
medline:
18
5
2021
entrez:
14
2
2021
Statut:
ppublish
Résumé
COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2 but binding antibodies are also detected in prepandemic individuals, indicating potential crossreactivity with common cold human coronaviruses (HCoV) and questioning its utility in seroprevalence studies. We investigated the immunogenicity of the full-length and shorter fragments of the SARS-CoV-2 N protein, and the crossreactivity of antibodies with HCoV. We identified a C-terminus region in SARS-CoV2 N of minimal sequence homology with HCoV that was more specific for SARS-CoV-2 and highly immunogenic. IgGs to the full-length SARS-CoV-2 N also recognized N229E N, and IgGs to HKU1 N recognized SARS-CoV-2 N. Crossreactivity with SARS-CoV-2 was stronger for alpha- rather than beta-HCoV despite having less sequence identity, revealing the importance of conformational recognition. Higher preexisting IgG to OC43 N correlated with lower IgG to SARS-CoV-2 N in rRT-PCR negative individuals, reflecting less exposure and indicating a potential protective association. Antibodies to SARS-CoV-2 N were higher in patients with more severe and longer duration of symptoms and in females. IgGs remained stable for at least 3 months, while IgAs and IgMs declined faster. In conclusion, N protein is a primary target of SARS-CoV-2-specific and HCoV crossreactive antibodies, both of which may affect the acquisition of immunity to COVID-19.
Identifiants
pubmed: 33582244
pii: S1931-5244(21)00029-3
doi: 10.1016/j.trsl.2021.02.006
pmc: PMC7879156
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Coronavirus Nucleocapsid Proteins
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-74Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Clin Diagn Lab Immunol. 2005 Jul;12(7):848-54
pubmed: 16002634
Viruses. 2020 Feb 25;12(3):
pubmed: 32106567
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
J Infect Dis. 2005 Jun 15;191(12):2033-7
pubmed: 15897988
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
Biochem Biophys Res Commun. 2020 Jun 30;527(3):618-623
pubmed: 32416961
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Clin Microbiol Infect. 2020 Nov;26(11):1557.e1-1557.e7
pubmed: 32745595
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Clin Infect Dis. 2021 Jun 15;72(12):e1004-e1009
pubmed: 33252659
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Nat Commun. 2021 Jan 4;12(1):6
pubmed: 33397903
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32997649
J Microbiol Biotechnol. 2008 Oct;18(10):1717-21
pubmed: 18955825
PLoS Pathog. 2020 Aug 21;16(8):e1008762
pubmed: 32822426
J Clin Microbiol. 2020 Sep 22;58(10):
pubmed: 32747400
Antiviral Res. 2005 Feb;65(2):69-78
pubmed: 15708633
Am J Clin Pathol. 2020 Oct 13;154(5):620-626
pubmed: 32814955
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Clin Virol. 2020 Aug;129:104468
pubmed: 32485620
J Infect Dis. 2004 Jul 15;190(2):379-86
pubmed: 15216476
J Virol. 2020 Jan 31;94(4):
pubmed: 31776274
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
J Biol Chem. 2006 Apr 21;281(16):10669-81
pubmed: 16431923
J Clin Microbiol. 2005 Aug;43(8):3718-26
pubmed: 16081901
Viruses. 2014 Aug 07;6(8):2991-3018
pubmed: 25105276
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Virus Res. 2014 Dec 19;194:175-83
pubmed: 24670324
J Infect Dis. 2021 Jan 4;223(1):62-71
pubmed: 33175145
Nat Commun. 2021 Jun 18;12(1):3781
pubmed: 34145263
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
J Autoimmun. 2017 Sep;83:12-21
pubmed: 28479213
Clin Chem. 2003 Dec;49(12):1989-96
pubmed: 14633869
Clin Chem. 2004 Jun;50(6):988-95
pubmed: 15054081
Antiviral Res. 2014 Mar;103:39-50
pubmed: 24418573
JAMA. 2020 May 26;323(20):2085-2086
pubmed: 32293646
Immunity. 2020 Dec 15;53(6):1258-1271.e5
pubmed: 33296686
J Clin Microbiol. 2004 May;42(5):2306-9
pubmed: 15131220
Virus Res. 2015 Oct 2;208:136-45
pubmed: 26103099
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2021 May 14;372(6543):738-741
pubmed: 33846272
J Vet Sci. 2010 Jun;11(2):165-7
pubmed: 20458159
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
J Virol. 2008 Jul;82(14):6962-71
pubmed: 18448518
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33127841
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Sci Rep. 2019 Feb 4;9(1):1390
pubmed: 30718599
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Immunol Lett. 2008 Jun 15;118(1):65-71
pubmed: 18440652
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
mBio. 2020 Sep 25;11(5):
pubmed: 32978311
Clin Infect Dis. 2021 Apr 8;72(7):1291-1292
pubmed: 32445559
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859